Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

101

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States : a population-based study

enthalten in: Leukemia & lymphoma | 2021

von Al Hadidi, S. | Dongarwar, D. | Salihu, H. | +7

102

A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens : once-weekly and twice-weekly

enthalten in: Expert review of hematology | 2021

von Leleu, X. | Chari, A. | Richard, S. | +3

103

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical drug investigation | 2021

von Weisel, K. | Martin, T. | Krishnan, A. | +14

104

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical drug investigation | 2021

von Weisel, K. | Martin, T. | Krishnan, A. | +14

105

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical drug investigation | 2021

von Weisel, K. | Martin, T. | Krishnan, A. | +14

106

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Facon, T. | Kumar, S. | Plesner, T. | +26

107

Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Jakubowiak, A. | Usmani, S. | Krishnan, A. | +8

108

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

enthalten in: Transplantation and cellular therapy | 2021

von Holstein, S. | Bahlis, N. | Bergsagel, P. | +20

109

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

enthalten in: Cancer medicine | 2021

von Foureau, D. | Bhutani, M. | Guo, F. | +8

110

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

enthalten in: Current medical research and opinion | 2021

von Martin, T. | Usmani, S. | Schecter, J. | +14

ErratumIn: Curr Med Res Opin. 2021 Oct 6;:1-12. - PMID 34612784